Ready Capital Corporation 5.75%
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ready Capital Corporation is a multi-strategy real estate finance company specializing in originating, acquiring, financing, and servicing small- to medium-sized balance commercial real estate loans. The company’s core products and services include loans backed by commercial real estate such as agency multifamily, investor, construction, bridge-to-stabilization, fixed-to-stabilization, and agency loans. It also provides U.S. Small Business Administration (SBA) 7(a) loans and USDA OneRD loans targeted at small businesses and traditionally underbanked communities. Operations span the United States, with a strategic focus on the lower-to-middle-market (LMM) segment, serving investor and owner-occupied commercial real estate clients. Ready Capital operates through subsidiaries ReadyCap Commercial, LLC for commercial real estate loans and ReadyCap Lending, LLC for SBA and small business lending. Founded in 2013 and headquartered in New York, the company has demonstrated active acquisition strategies, including public company mergers and growth via acquisitions. In recent developments, Ready Capital completed the acquisition of United Development Funding IV (UDF IV) in early 2025, expanding its portfolio with a land development lending platform concentrated in the Dallas-Fort Worth residential market. This acquisition diversifies Ready Capital’s offerings by incorporating residential land loans and enhances its residential construction lending platform, enabling expansion into new markets with strong fundamentals. Additionally, the company has integrated new loan origination and servicing platforms through acquisitions such as Funding Circle, boosting its small business lending capabilities. Ready Capital also completed its transformative acquisition of Broadmark Realty Capital in 2023, enhancing its financial scale and product mix. The company recently announced a new share repurchase program and actively manages a diversified portfolio that balances agency multifamily, construction, bridge, and small business loans, maintaining a conservative credit approach focused on superior markets and strong sponsors. These strategic acquisitions, platform expansions, and active portfolio management position Ready Capital as a leading non-bank SBA 7(a) lender (ranked #1 non-bank and #4 overall SBA lender) and a significant multi-strategy real estate finance entity in the lower-to-middle-market commercial real estate and small business lending sectors in the U.S. The company's broad geographic footprint and diversified loan portfolio enable it to serve a wide range of customers from commercial real estate investors and developers to small business borrowers seeking SBA-backed financing. Ready Capital continues to emphasize growth through accretive acquisitions, expanding product offerings, and operational efficiencies to enhance shareholder value and market presence. This description reflects data current through late 2025.
Bitcoin Meets Sustainability: 7RCC Launches Crypto & Carbon Credit ETF
7RCC Spot Bitcoin and Carbon Credit Futures ETF (NYSE Arca: BTCK) Begins Trading
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
Comstock Announces Summerbration 2026 at Reston Station
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Ready Capital Corporation (RC) Q2 2025 Earnings Call Transcript
Ready Capital: Value Destruction Proceeds On Schedule
Ready Capital Corporation (RC) Q3 2025 Earnings Call Transcript
I Came In Like A Ready Capital!
Ready Capital Corporation (RC) Q3 2025 Earnings Call Transcript
Attractive Short-Dated Bond, 8.5% YTM, From Ready Capital
Ready Capital Corporation (RC) Q1 2025 Earnings Call Transcript
Preferreds/Bond Weekly Review: Couple Of New Issues
Better Options Than This 8% Baby Bond From Ready Capital
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
Government signs significant agreement with UAE company to revamp UTCL
Former Rubaga RCC to Join Elective Politics in 2026